-+ 0.00%
-+ 0.00%
-+ 0.00%

Evommune says Phase 2a trial shows EVO301 cuts EASI 55% at Week 12 in atopic dermatitis

PUBT·10/01/2026 12:03:56
Evommune says Phase 2a trial shows EVO301 cuts EASI 55% at Week 12 in atopic dermatitis
  • Evommune presented additional Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.
  • Trial results showed clear symptom improvement versus placebo, with responses continuing to build weeks after the second dose.
  • Safety profile was broadly comparable to placebo, supporting further development and differentiation from existing biologics.
  • Plans set to start a global, dose-optimized Phase 2b trial using a subcutaneous formulation in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001558140) on October 01, 2026, and is solely responsible for the information contained therein.